Investing in the wake of a pandemic

We’ve witnessed dramatic fiscal and monetary responses to the COVID-19 pandemic by governments across the world. Now we must look at how that stimulus is likely to evolve and consider the longer-term outlook for stock markets in this context.

From an investment perspective, we can broadly view the evolution of the pandemic in three stages:

  • Income stimulus
  • The reopening
  • Infrastructure stimulus

At stage one, as money has been transferred from governments to households, the major beneficiaries have been secular growers that have benefited from a world in lockdown – these are a narrow set of winners.

Stage one beneficiaries in Antipodes’ portfolio include social commerce and software incumbents such Facebook, Microsoft and Alibaba. As well as pharmaceutical stocks such as Merck, Roche and Sanofi. Lowes – which has benefited from increased DIY activity – has also rebounded with strength.

On the margin, however, we are of the opinion that now is the time to begin allocating away from stage one winners to stage two and stage three opportunities.

At stage two (the reopening) we are looking at dislocated category leaders that may come out of the pandemic with less competition.

At this point it is important to remember that in many areas of the market we don’t see the pre-COVID-19 status quo resuming. Businesses have learnt to do things with less – in particular, cost cutting will likely result in slower than expected employment recovery, reductions in business travel and easing office demand.

Strong retail banks and under-the-radar omnichannel retail leaders are among the stage two beneficiaries.

The shift to infrastructure stimulus

The economies that are best able to kick-start real investment will emerge from COVID-19 strongest.

The fact is, income stimulus is simply a transfer payment which can only ever be a short-term measure. Ultimately, governments that have focused on income stimulus, such as the US, will need to pivot towards infrastructure spending to generate meaningful investment to strengthen their economies.

We see infrastructure stimulus as the third stage in the recovery evolution.

At present, China and Europe are ahead in the progression to major infrastructure stimulus with decarbonisation, electric vehicles and 5G adoption at the forefront. The market beneficiaries lie in more economically cyclical businesses, many of them currently trading on historically low multiples.

Three Antipodes’ holdings that are positioned to outperform when stimulus switches from income protection to investment include Siemens, Electricite de France (EDF) and Continental.

As we recently wrote, various signals suggest that tomorrow’s market winners are today’s misunderstood lower multiple stocks. The tailwind of major infrastructure stimulus strengthens the case.

The recovery risks 

Investors must keep in mind the downside risks that could potentially derail a broad transition from lockdowns and income stimulus to investment stimulus.

In the US, we are faced with an unpredictable environment when it comes to policy makers. The withdrawal of income stimulus packages ahead of the release of any infrastructure stimulus is a risk that needs to be watched closely.

We are also monitoring the US-China rivalry. Further escalation in tensions could also become a headwind.

Finally, as COVID-19 continues to spread in many parts of the world, we must be mindful of a ‘second wave’ and how that could exacerbate social unrest and populism.

We take a multi-layered approach to risk management. It begins with owning businesses that provide multiple ways of winning. We also look for uncorrelated sources of alpha and use our macro observations to feed into the margin of safety we require to own a stock.

Around the edges, we look for tail risk protection – insurance to protect our portfolios against the unpredictable.

Webinar – Stages and challenges of reopening

This webinar was presented live on 4 June, 2020. To watch the full presentation, click here.

 


This communication was prepared by Antipodes Partners Limited (ABN 29 602 042 035, AFSL 481 580) (Antipodes). Antipodes believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. This communication is for general information only and was prepared for multiple distribution and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. Persons relying on this information should do so in light of their specific investment objectives and financial situations. Any person considering action on the basis of this communication must seek individual advice relevant to their particular circumstances and investment objectives. Subject to any liability which cannot be excluded under the relevant laws, Antipodes disclaim all liability to any person relying on the information contained on this website in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.
Any opinions or forecasts reflect the judgment and assumptions of Antipodes on the basis of information at the date of publication and may later change without notice. Any projections are estimates only and may not be realised in the future. Information on this website is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained on the website is prohibited without obtaining prior written permission from Antipodes.
Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 is the product issuer of funds managed by Antipodes.  Any potential investor should consider the relevant Product Disclosure Statement available at www.antipodesonespartners.com when deciding whether to acquire, or continue to hold units in a fund. The issuer is not licensed to provide financial product advice.  Please consult your financial adviser before making a decision. Past performance is not a reliable indicator of future performance.
17 June 2020
Jacob Mitchell, Chief Investment Officer and Lead Portfolio Manager